Thanks for your interest in the ADPKD Referral tool. We are helping connect referring doctors to specialists interested in caring for patients with autosomal dominant polycystic kidney disease (ADPKD).
Are you interested in being added as a provider, click below to update us with your office/clinic information
Demo Login
Nephrology Ask the Experts
UKidney answers your nephrology questions! Feel free to search our previous submissions or create your own today.
I realize that the TEMPO study suggests tolvaptan be used in patients with intact renal function (that is who they enrolled) but have you been using it for later stage CKD as well?
During the TEMPO trial patients with CKD function 1,2 and 3 were enrolled and found to benefit from tolvaptan, that is less kidney enlargment and less deterioration of renal function(as compared to placebo). There were no stage 4 patients, therefore the benefit here is not demonstrated but is presently being tested in an ongoing study (REPRISE).
Page :
1
There are no replies made for this post yet. Be one of the first to reply to this post!
Submit Your Response
Don't miss SGLT Tools - PowerPoint slide library for SGLT2 inhibitors
You are logged in with standard UKidney account. In some cases, UKidney content is restricted to verified Healthcare Providers (HCPs) only.
If you would like to upgrade your account to a UKidney Verified Profile, please click below. There is no cost to do this but proof of HCP status is requried.
ukidneyisup
You are now being logged in using your Facebook credentials